KUR-101 is under clinical development by Atai Life Sciences and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KUR-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KUR-101 overview
KUR-101 (deuterated mitragynine) is under investigation for the treatment of pain and opioid use disorder. The drug candidate is a synthetic derivative of alkaloid derived from Mitragyna speciosa plant (kratom) and acts by targeting human mu opioid receptors and human Kappa opioid receptors. It is administered through oral route.
Atai Life Sciences overview
Atai Life Sciences (ALS) is a biotechnology company that develops innovative treatments for addressing depression, anxiety, addiction, other unmet medical needs and mental health disorders. It aims to accelerate the development of new medicines across all its companies to receive clinically meaningful, and sustained behavioral change in mental health of patients. The company has its offices in New York, London and Berlin. ALS is headquartered in Berlin, Germany.
For a complete picture of KUR-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
